LIM-0705

Phase 2Small molecule

LLimerick BioPharma

LIM-0705 is one of 23 small molecule programs targeting Impaired glucose tolerance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Impaired Glucose ToleranceActive, not recruiting

Impaired Glucose TolerancePhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Impaired Glucose Tolerance

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

3 2

Avandia

Alnylam Pharmaceuticals

Approved

2 3

Zocor

OOrganon and Co

Approved

1 4

Curcumin

Merck & Co.

Approved

1 5

Galvus

Novartis

Phase 3

1 6

Ilaris

Novartis

Phase 2

1 7

Januvia

ZZydus Therapeutics Inc.

Phase 2

3 8

Nebivolol 2

FForest Laboratories

Approved

1 9

GFT505

GGenfit

Phase 2

1 10

Azeliragon

CCantex Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Impaired glucose tolerance2 trials

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

Withdrawn·LLimerick BioPharma·Phase 1·NCT01093677·30 enrolled

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

Unknown status·LLimerick BioPharma·Phase 2·NCT01364155·50 enrolled

Unspecified1 trial

Safety and Tolerability of LIM-0705 in Healthy Male Subjects

Completed·LLimerick BioPharma·Phase 1·NCT01060475·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LIM-0705. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LIM-0705 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LIM-0705. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Limerick BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLimerick BioPharma

LIM-0705

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Impaired glucose tolerance2 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News